Rhythm Says European Medicines Agency's CHMP Adopted Positive Opinion Recommending Marketing Authorization For IMCIVREE; European Commission Decision Anticipated In H2 Of 2024

6/28/24 8:02:51 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RYTM alert in real time by email

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization for IMCIVREE (setmelanotide) include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.

Get the next $RYTM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RYTM

Date	Price Target	Rating	Analyst
10/21/2024	$70.00	Buy	Guggenheim
9/18/2024	$64.00	Buy	H.C. Wainwright
9/17/2024	$64.00	Mkt Outperform	JMP Securities
5/8/2024	$49.00 → $42.00	Buy → Neutral	BofA Securities
12/19/2023	$29.00 → $55.00	Equal-Weight → Overweight	Morgan Stanley
8/1/2023	$22.00 → $27.00	Neutral → Buy	BofA Securities
1/18/2023	$52.00	Buy	Canaccord Genuity
8/8/2022	$28.00	Neutral → Buy	Goldman

More analyst ratings

$RYTM
Press Releases

Fastest customizable press release news feed in the world

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). "We believe there is a significant need and opportunity with the growing awareness of BBS to better understand the disease and its epidemiology," said Prof. Phil Beales, Axovia Therapeutics' Chief Executive Officer and Co-Founder. "At Axovia, we are utilizing gene therapy to address the loss of sight and obesity experienced by patients with BBS, and we are pleased to be collaborating with Rhythm, a global company that has pioneered research in the mel
10/24/24 6:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
-- Five posters to be presented at ObesityWeek® -- BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 5:00 p.m. ET on Tuesday, November 5, 2024 to report its third quarter 2024 financial results and provide a corporate update. The conference call will be hosted live from The Obesity Society's Annual Meeting, ObesityWeek® in San Antonio, TX. To access the live conference call, participants may register here. While not required, it is recommended that pa
10/23/24 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees. These inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan"). The Inducement Plan is used exclusively for the grant of equity awards
10/8/24 4:01:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

$RYTM
Financials

Live finance-specific insights

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
-- Five posters to be presented at ObesityWeek® -- BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 5:00 p.m. ET on Tuesday, November 5, 2024 to report its third quarter 2024 financial results and provide a corporate update. The conference call will be hosted live from The Obesity Society's Annual Meeting, ObesityWeek® in San Antonio, TX. To access the live conference call, participants may register here. While not required, it is recommended that pa
10/23/24 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
-- Second quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $29.1 million -- -- Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial evaluating setmelanotide in hypothalamic obesity; On track for topline data from 120-patient, pivotal cohort in 1H 2025 -- -- Completed sNDA submission seeking to expand U.S. label of IMCIVREE to treat pediatric patients as young as 2 years old in approved indications -- -- Cash on-hand expected to support planned operations into 2026 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global
8/6/24 7:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 6, 2024 to report its second quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. Also today, Rhythm announced that David Meeker, M.D., Chair, President and Chi
7/23/24 7:30:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair "Al" Garfield, Ph.D. as Chief Scientific Officer, effective July 1. "We are excited to welcome Al back to Rhythm as we continue to leverage our understanding of the melanocortin-4 receptor (MC4R) pathway to bring potential therapies to patients and their families," said David Meeker, M.D., Rhythm Chairman, Chief Executive Officer and President. "Al's leadership and established scientific expertise and experience
7/8/24 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the appointment of Dana Washburn, M.D., as Senior Vice President of Clinical Development and as a member of the Company's Executive Leadership Team, effective September 26, 2022. As SVP of Clinical Development, Dr. Washburn will lead the Company's robust clinical development program, clinical operations, and data management. "Dr. Washburn is a collaborative, resourceful leade
10/6/22 4:02:00 PM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care
Wren Appoints Bart Henderson as Chief Executive Officer
Wren Therapeutics, a biopharmaceutical company transforming drug discovery for neurodegenerative diseases, today announced the appointment of Bart Henderson as Chief Executive Officer. Wren's unique drug discovery platform harnesses advances in the biophysics of protein assembly dynamics to target the toxic fleeting protein intermediates, the oligomers, in neurodegenerative disease pathways, and discover small molecules that can block their generation with precision. Bart brings broad leadership experience in the biotechnology industry as a founder and co-founder of several companies including Torque (now Repertoire Immune Medicines), Rhythm (NASDAQ:RYTM) and its subsidiary Motus (acquired
3/4/22 8:00:00 AM ET
$RYTM
Biotechnology: Pharmaceutical Preparations
Health Care

Rhythm Says European Medicines Agency's CHMP Adopted Positive Opinion Recommending Marketing Authorization For IMCIVREE; European Commission Decision Anticipated In H2 Of 2024

Chat with this insight

Recent Analyst Ratings for $RYTM

$RYTM Press Releases

Fastest customizable press release news feed in the world

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

$RYTM SEC Filings

Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

SEC Form 144 filed by Rhythm Pharmaceuticals Inc.

$RYTM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Good Jennifer L exercised 31,751 shares at a strike of $21.54 and sold $1,663,803 worth of shares (31,751 units at $52.40) (SEC Form 4)

Chief Human Resources Officer Cramer Pamela J. exercised 4,099 shares at a strike of $19.02 and sold $205,062 worth of shares (4,099 units at $50.03) (SEC Form 4)

Director Tetrault Lynn A. exercised 20,700 shares at a strike of $11.82 and sold $1,028,991 worth of shares (20,700 units at $49.71) (SEC Form 4)

$RYTM Financials

Live finance-specific insights

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

$RYTM Market Insights

Live Market Insights

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $55

Rhythm Pharmaceuticals First Patients Dosed In Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 In Hypothalamic Obesity

$RYTM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Guggenheim initiated coverage on Rhythm Pharmaceuticals with a new price target

H.C. Wainwright initiated coverage on Rhythm Pharmaceuticals with a new price target

JMP Securities initiated coverage on Rhythm Pharmaceuticals with a new price target

$RYTM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Rhythm Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Rhythm Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Rhythm Pharmaceuticals Inc. (Amendment)

$RYTM Leadership Updates

Live Leadership Updates

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Wren Appoints Bart Henderson as Chief Executive Officer

Recent Analyst Ratings for
$RYTM

$RYTM
Press Releases

$RYTM
SEC Filings

$RYTM
Insider Trading

$RYTM
Financials

$RYTM
Market Insights

$RYTM
Analyst Ratings

$RYTM
Large Ownership Changes

$RYTM
Leadership Updates